Kamada Stock Forecast, Price & News

Wall Street analysts have given Kamada a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kamada wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Kamada is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for Kamada.

Kamada Ltd. (NASDAQ:KMDA) released its earnings results on Wednesday, August, 11th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.05 by $0.03. Kamada had a trailing twelve-month return on equity of 6.73% and a net margin of 10.42%.
View Kamada's earnings history.

Kamada's stock was trading at $5.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KMDA shares have increased by 4.3% and is now trading at $5.37.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Kamada include Vanda Pharmaceuticals (VNDA), Stoke Therapeutics (STOK), Gracell Biotechnologies (GRCL), BELLUS Health (BLUSF), Rani Therapeutics (RANI), POINT Biopharma Global (PNT), Design Therapeutics (DSGN), BeyondSpring (BYSI), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), Crinetics Pharmaceuticals (CRNX), Phibro Animal Health (PAHC), Akero Therapeutics (AKRO), Avidity Biosciences (RNA) and BioXcel Therapeutics (BTAI).
View all of KMDA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Kamada's stock is owned by a variety of institutional and retail investors. Top institutional investors include Jefferies Group LLC (0.00%), Renaissance Technologies LLC (2.52%), ARK Investment Management LLC (2.06%), Vanguard Group Inc. (1.70%), Jefferies Group LLC (0.00%) and Group One Trading L.P. (0.00%).

KMDA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and JPMorgan Chase & Co..

KMDA stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Jefferies Group LLC, Group One Trading L.P., SG3 Management LLC, Wolverine Trading LLC, Cutler Group LP, ARK Investment Management LLC, and Seizert Capital Partners LLC.

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KMDA stock can currently be purchased for approximately $5.37.

Kamada has a market capitalization of $239.07 million and generates $133.25 million in revenue each year. The biotechnology company earns $17.14 million in net income (profit) each year or $0.38 on an earnings per share basis.

Kamada employs 408 workers across the globe.

The official website for Kamada is www.kamada.com.

Kamada is headquartered at 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402.

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at (728) 940-6472 or via email at [email protected]